NNI-351 is an orally active inhibitor of DYRK1ATooltip dual specificity tyrosine-phosphorylation-regulated kinase 1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. In July 2022, NNI-351 was granted orphan drug status by the FDA for the treatment of Fragile X syndrome.
See also List of investigational antidepressants
References
External links NNI-351 - NeuroNascent, Inc NNI-351 - AdisInsight Methods and pharmaceutical compositions for treating down syndrome (patent)